Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report released on Saturday morning. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Down 2.4 %

BTX stock opened at $0.57 on Friday. The business has a 50 day moving average price of $0.39 and a 200 day moving average price of $1.06. The stock has a market cap of $33.30 million, a price-to-earnings ratio of -0.25 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $10.10.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.